New stock news | Hui Lun Medicine plans Hong Kong stock IPO. The China Securities Regulatory Commission requires additional clarification on whether full social security and provident fund payments have been made, as well as whether it constitutes a major violation of laws and regulations.

On June 5th, the China Securities Regulatory Commission issued the "Supplementary Materials Requirements for Overseas Issuance and Listing (June 1, 2026 - June 5, 2026)". The International Department of the China Securities Regulatory Commission required supplementary materials from 10 enterprises. Among them, Hulun Medicine was required to provide further clarification on the specific situation of its subsidiaries' insufficient payment of social insurance and housing provident fund, and whether it constitutes a major violation of laws and regulations. According to the disclosure by the Hong Kong Stock Exchange on April 2nd, Hulun Medicine submitted an application for listing on the main board of the Hong Kong Stock Exchange, with CITIC Securities as its exclusive sponsor. The China Securities Regulatory Commission requested Hulun Medicine to provide clarification on the following issues, and requested lawyers to conduct verification and provide clear legal opinions: 1. Please explain the pricing basis and actual payment of capital increases and share transfers by your company in the past, whether there is any failure to fulfill capital obligations, diversion of capital, or defects in capital contribution methods, and provide a clear conclusion on the legality and compliance of the establishment and past equity changes. 2. Regarding standardized operations: (1) Please explain the specific situation of insufficient payment of social insurance and housing provident fund by your company and its subsidiaries, whether it constitutes a major violation of laws and regulations, and whether it has a significant impact on this issuance and listing; (2) Please explain the latest progress of litigation cases involving your company, their impact on the company's operations and debt repayment ability, and whether they constitute substantial obstacles to this issuance and listing. 3. Regarding this issuance and listing and "full circulation": (1) Please explain the estimated amount of funds to be raised after the full exercise of the oversubscription rights; (2) Please explain whether the shares held by shareholders participating in "full circulation" in this offering have any defects such as pledging, freezing, or other rights issues. 4. Please explain the specific circumstances and reasons for the termination of the previous application for A-share listing guidance by your company, whether there are plans to continue with the A-share listing and specific arrangements, and whether there are any circumstances that may have a significant impact on this issuance and listing. The prospectus shows that Hulun Medicine is a pharmaceutical company with a good track record in drug development and commercialization. After years of continuous efforts, the company has established a comprehensive drug industry chain operation system covering research and development, production, and commercialization. Based on this foundation, the company is actively expanding its capabilities and focusing on innovative drugs for major diseases and critical illnesses as strategic priorities.